Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia (Q34016866)

30 July 2017

1 reference

title

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia (English)

1 reference

30 July 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

2

Hagop M Kantarjian

1 reference

30 July 2017

3

Jorge E Cortes

1 reference

30 July 2017

Alfonso Quintás-Cardama

series ordinal

1

1 reference

30 July 2017

1 April 2009

1 reference

30 July 2017

1 reference

30 July 2017

16

1 reference

30 July 2017

2

1 reference

30 July 2017

122-131

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

30 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Effect of cellular quiescence on the success of targeted CML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Chronic myeloid leukemia: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Cell cycle targets of Ras/Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Minimal residual disease in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600204

10.1177/107327480901600204

21 January 2018

Identifiers

DOI

0 references

PubMed ID

19337198

1 reference

PubMed ID

19337198